Terms ending in 2036
Every in-force patent on Pfizer Inc.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,653,764 | Immunogenic Compositions for Use in Pneumococcal Vaccines In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,135,279 | Immunogenic Compositions for Use in Pneumococcal Vaccines In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US D907,232 | Medical Testing Device In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,851,163 | Dosage Regimen for Madcam Antagonists In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,884,726 | Dosage Regimen For MAdCAM Antagonists In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US 9,765,073 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US D910,200 | Test Tube In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,888,611 | Neisseria Meningitidis Compositions and Methods Thereof In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,365,263 | Bifunctional Cytotoxic Agents Containing the Cti Pharmacophore In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 11,602,525 | Antibody-Drug Conjugates with High Drug Loading In force · High confidence | Pfizer Inc. | In force | High confidence | |
| 65 more term ends in 2036 · Pro | |||||
10 of 75 patents shown. Soonest term end first, then patent number.
Pro members see all 75.
72 of these are in force and held by Pfizer Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.